© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study
aDepartments of Cardiology, Karolinska Hospital, S-171 76 Stockholm, Sweden
bDepartment of Medicine, Karolinska Hospital, Stockholm, Sweden
cDepartment of Medicine, Sahlgrenska Hospital, Göteborg, Sweden
dDepartment of Medicine, Norrland University Hospital, Umeå, Sweden
eNordic School for Public Health, Göteborg, Sweden
* Corresponding author. Tel. +46 8 729-21-71; Fax +46 8 31-10-44.
Objectives: We analysed predictors of 1-year mortality following acute myocardial infarction in patients with diabetes mellitus by applying uni- and multivariate statistics on the DIGAMI cohort. Background: Diabetic patients with acute myocardial infarction have a poor prognosis. This may depend on a poor metabolic control, a hypothesis that was tested in DIGAMI, a prospective randomised study. In this trial institution of immediate intensive insulin treatment reduced 1-year mortality by 30%. Methods: We recruited 620 diabetic patients with acute myocardial infarction, 314 of whom served as controls, while the remaining 306 patients were treated with an acute insulin–glucose infusion followed by multidose subcutaneous insulin. Results: Age, previous myocardial damage, duration of the diabetes and previous insulin therapy were significantly related to 1-year mortality, while conventional risk factors lacked independent prognostic weight. Female sex was not linked to mortality when controlling for the confounding effects of other predictors. One of the strongest predictors of a fatal outcome, in particular during the hospital phase, was blood glucose at hospital admission. Beta-blockade appeared to exert a striking, independent secondary-preventive effect. Conclusions: It seems that good metabolic control and not conventional risk factors is of major importance for diabetic patients sustaining acute myocardial infarction. Also treatment with beta-blockade seems to be of special importance in this category of patients.
KEYWORDS Myocardial infarction; Diabetes; Mortality; Morbidity; Prediction; Beta-blockers; Insulin; Human
1 PhD on behalf of the DIGAMI study group.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Triplitt and C. A. Alvarez Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes Diabetes Spectr, July 1, 2008; 21(3): 177 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Radke and H. Schunkert Glucose-lowering therapy after myocardial infarction: more questions than answers Eur. Heart J., January 2, 2008; 29(2): 141 - 143. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mudespacher, D. Radovanovic, E. Camenzind, M. Essig, O. Bertel, P. Erne, F. R. Eberli, and F. Gutzwiller Admission glycaemia and outcome in patients with acute coronary syndrome Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 346 - 352. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Ahmad, R. A. Cherry, I. Lendel, D. T. Mauger, S. L. Service, L. J. Texter, and R. A. Gabbay Increased Hospital Morbidity Among Trauma Patients With Diabetes Mellitus Compared With Age- and Injury Severity Score-Matched Control Subjects Arch Surg, July 1, 2007; 142(7): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Dutka, M. Pitt, D. Pagano, M. Mongillo, D. Gathercole, R. S. Bonser, and P. G. Camici Myocardial Glucose Transport and Utilization in Patients With Type 2 Diabetes Mellitus, Left Ventricular Dysfunction, and Coronary Artery Disease J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2225 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. McDonald, S. R. Majumdar, J. L. Mahon, and J. A. Johnson The Effectiveness of {beta}-Blockers After Myocardial Infarction in Patients With Type 2 Diabetes: Response to Bell Diabetes Care, February 1, 2006; 29(2): 483 - 484. [Full Text] [PDF]
|
|
|
|
|
|
M. Bartnik, K. Malmberg, and L. Ryden Management of patients with type 2 diabetes after acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 144 - 154. [Abstract] [PDF]
|
|
|
|
 |
|
 A. D M Stork, H. Kemperman, D W. Erkelens, and T. F Veneman Comparison of the accuracy of the hemocue glucose analyzer with the Yellow Springs Instrument glucose oxidase analyzer, particularly in hypoglycemia Eur. J. Endocrinol., August 1, 2005; 153(2): 275 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nodari, M. Metra, A. D. Cas, and L. D. Cas Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus Eur J Heart Fail, December 1, 2003; 5(6): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Westphal and P. J. Palumbo Insulin and Oral Hypoglycemic Agents Should Not Be Used in Combination in the Treatment of Type 2 Diabetes Arch Intern Med, August 11, 2003; 163(15): 1783 - 1785. [Full Text] [PDF]
|
|
|
|
|
|
P. Dandona, A. Aljada, and A. Bandyopadhyay The Potential Therapeutic Role of Insulin in Acute Myocardial Infarction in Patients Admitted to Intensive Care and in Those With Unspecified Hyperglycemia Diabetes Care, February 1, 2003; 26(2): 516 - 519. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gheorghiade and S. Goldstein {beta}-Blockers in the Post-Myocardial Infarction Patient Circulation, July 23, 2002; 106(4): 394 - 398. [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Umpierrez, S. D. Isaacs, N. Bazargan, X. You, L. M. Thaler, and A. E. Kitabchi Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 978 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Kersten, M. W. Montgomery, T. Ghassemi, E. R. Gross, W. G. Toller, P. S. Pagel, and D. C. Warltier Diabetes and hyperglycemia impair activation of mitochondrial KATP channels Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1744 - H1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Klamann, P Sarfert, V Launhardt, G Schulte, W.H Schmiegel, and M.A Nauck Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) Eur. Heart J., February 1, 2000; 21(3): 220 - 229. [Abstract] [PDF]
|
|
|
|
|
|
J. Chen, T. A. Marciniak, M. J. Radford, Y. Wang, and H. M. Krumholz Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients: Results from the national cooperative cardiovascular project J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1388 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kersten, T. J. Schmeling, K. G. Orth, P. S. Pagel, and D. C. Warltier Acute hyperglycemia abolishes ischemic preconditioning in vivo Am J Physiol Heart Circ Physiol, August 1, 1998; 275(2): H721 - H725. [Abstract] [Full Text] [PDF]
|
|